Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register

Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents, etanercept, juvenile idiopathic arthritis (JIA), longitudinal studies and outcomes

Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals in Children register previously showed that disability and health related quality of life (HRQoL) improved shortly after treatment with etanercept. Our aim was to investigate long term functional outcome, HRQoL and treatment changes in the same patients, who started etanercept >5 years ago.

Methods: Patients were traced and questioned on education and employment. Data on recent disease status, comorbidities and structural damage were retrieved. Disability was assessed by (Child) Health Assessment Questionnaire ((C)HAQ), HRQoL was measured by Child Health Questionnaire, Short Form 36 and Health Utilities Index Mark 3. Linear mixed models were used to analyze changes over time.

Results: 43 patients (81% response) started etanercept median 8.5 years (IQR: 7.7-10.3) ago. Median age was 22 years (IQR: 18-24). 42% had a (C)HAQ of 0.00. HRQoL was similar to HRQoL shortly after start of etanercept, except for the domains bodily pain and general health perception, which deteriorated to levels comparable to those at start of etanercept. VAS pain also worsened (median 12 (IQR:2-43)), but not to the extent as the bodily pain domain on the SF-36.The unemployment rate (12%) was comparable to the general population; educational level was higher (77% of patients >17 years had achieved at least upper secondary education). 40% of patients switched to other biologic agents, 40% were still using etanercept and 20% were off anti-rheumatic treatment. 14% had had joint surgery. There were no reports of malignancies.

Conclusion: The improvement in HRQoL after start of etanercept was sustained after 8.5 years. Disability was low. On many aspects of daily life, patients functioned comparably to or better than the general population. The need for surgery for 14% of patients stresses the importance of early treatment of JIA. Chronic pain – even when the disease is inactive – remains an important issue that should not be overlooked.

Disclosure:

J. Anink,
None;

F. Prince,
None;

M. Dijkstra,
None;

M. H. Otten,
None;

M. Twilt,
None;

R. ten Cate,

Pfizer Inc,

S. Gorter,
None;

Y. Koopman-Keemink,
None;

M. A. J. Van Rossum,
None;

E. P. A. Hoppenreijs,
None;

L. W. A. van Suijlekom-Smit,

Pfizer Inc,

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-functional-outcome-and-quality-of-life-of-patients-with-refractory-juvenile-idiopathic-arthritis-treated-with-etanercept-results-of-the-dutch-arthritis-and-biologicals-in-children-register/